活体皮肤等效物治疗遗传性表皮松解症的疗效

Q4 Medicine Vestnik dermatologii i venerologii Pub Date : 2023-12-18 DOI:10.25208/vdv16249
A. Karamova, A. Kubanov, Ekaterina Vorotelyak, Olga Rogovaya, V. Chikin, Mariya A. Nefedova, E. Monchakovskaya
{"title":"活体皮肤等效物治疗遗传性表皮松解症的疗效","authors":"A. Karamova, A. Kubanov, Ekaterina Vorotelyak, Olga Rogovaya, V. Chikin, Mariya A. Nefedova, E. Monchakovskaya","doi":"10.25208/vdv16249","DOIUrl":null,"url":null,"abstract":"Background: inherited epidermolysis bullosa is a group of genetic skin disorders caused by mutations in genes encoding structural proteins of epidermis and dermo-epidermal junction. Clinical manifestations are characterized by spontaneous or trauma-induced skin and/or mucosal blistering, and extensive wounds. Cell therapy is considered to be a perspective therapeutic approach in improving wound healing process. \n Aims: to assess safety and efficacy of human skin equivalent in the treatment of inherited epidermolysis bullosa patients \n Materials and methods: 7 patients (5 female and 2 male subjects from the age of 20 to 55) with inherited epidermolysis bullosa with different clinical subtypes were enrolled in the study: 3 patients with intermediate recessive dystrophic epidermolysis bullosa, 2 patients with severe recessive dystrophic epidermolysis bullosa, 1 patient with dominant dystrophic epidermolysis bullosa and 1 patient with junctional epidermolysis bullosa. Transplantation of composite allogeneic living skin equivalent comprising allogeneic keratinocytes and fibroblasts in low concentration (5 mg/ml) embedded within a type I collagen gel matrix was performed. The living skin equivalent was developed at N.K. Koltsov Institute of Developmental Biology. 19 erosions and ulcers with a surface area between 0,4 cm2 and 120 cm2 were evaluated. At day 14 clinical assessment was performed. To assess level of expression immunofluorescence antigen mapping was used. \n Results: at day 14 complete erosion closure was achieved in 10 (53%) erosions. 4 (21%) erosions reduced in size 75%. Size reduction between 25% and 75% was shown in a single (5%) case. No clinical efficacy was demonstrated in 4 (21%) cases. Collagen VII expression increased comparing to baseline level and accompanied clinical improvement. \n Conclusions: the obtained data showed clinical efficacy of topical treatment with living skin equivalent, although no statistically significant difference was seen between living skin equivalent and atraumatic non-adhesive dressings. \n Keywords: inherited epidermolysis bullosa, junctional epidermolysis bullosa, recessive dystrophic epidermolysis bullosa, erosions, healing, topical treatment.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"13 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of human living skin equivalent in the treatment of inherited epidermolysis bullosa\",\"authors\":\"A. Karamova, A. Kubanov, Ekaterina Vorotelyak, Olga Rogovaya, V. Chikin, Mariya A. Nefedova, E. Monchakovskaya\",\"doi\":\"10.25208/vdv16249\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: inherited epidermolysis bullosa is a group of genetic skin disorders caused by mutations in genes encoding structural proteins of epidermis and dermo-epidermal junction. Clinical manifestations are characterized by spontaneous or trauma-induced skin and/or mucosal blistering, and extensive wounds. Cell therapy is considered to be a perspective therapeutic approach in improving wound healing process. \\n Aims: to assess safety and efficacy of human skin equivalent in the treatment of inherited epidermolysis bullosa patients \\n Materials and methods: 7 patients (5 female and 2 male subjects from the age of 20 to 55) with inherited epidermolysis bullosa with different clinical subtypes were enrolled in the study: 3 patients with intermediate recessive dystrophic epidermolysis bullosa, 2 patients with severe recessive dystrophic epidermolysis bullosa, 1 patient with dominant dystrophic epidermolysis bullosa and 1 patient with junctional epidermolysis bullosa. Transplantation of composite allogeneic living skin equivalent comprising allogeneic keratinocytes and fibroblasts in low concentration (5 mg/ml) embedded within a type I collagen gel matrix was performed. The living skin equivalent was developed at N.K. Koltsov Institute of Developmental Biology. 19 erosions and ulcers with a surface area between 0,4 cm2 and 120 cm2 were evaluated. At day 14 clinical assessment was performed. To assess level of expression immunofluorescence antigen mapping was used. \\n Results: at day 14 complete erosion closure was achieved in 10 (53%) erosions. 4 (21%) erosions reduced in size 75%. Size reduction between 25% and 75% was shown in a single (5%) case. No clinical efficacy was demonstrated in 4 (21%) cases. Collagen VII expression increased comparing to baseline level and accompanied clinical improvement. \\n Conclusions: the obtained data showed clinical efficacy of topical treatment with living skin equivalent, although no statistically significant difference was seen between living skin equivalent and atraumatic non-adhesive dressings. \\n Keywords: inherited epidermolysis bullosa, junctional epidermolysis bullosa, recessive dystrophic epidermolysis bullosa, erosions, healing, topical treatment.\",\"PeriodicalId\":23618,\"journal\":{\"name\":\"Vestnik dermatologii i venerologii\",\"volume\":\"13 4\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vestnik dermatologii i venerologii\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.25208/vdv16249\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vestnik dermatologii i venerologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25208/vdv16249","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景:遗传性表皮松解症是一组遗传性皮肤病,由编码表皮和真皮-表皮交界处结构蛋白的基因突变引起。临床表现以自发或创伤诱发的皮肤和/或粘膜水疱和大面积伤口为特征。细胞疗法被认为是改善伤口愈合过程的一种治疗方法。 目的:评估人皮等效物治疗遗传性大疱性表皮松解症患者的安全性和有效性 材料和方法:研究共招募了 7 名不同临床亚型的遗传性大疱性表皮松解症患者(5 名女性和 2 名男性,年龄在 20 至 55 岁之间):3名中度隐性萎缩性表皮松解症患者、2名重度隐性萎缩性表皮松解症患者、1名显性萎缩性表皮松解症患者和1名交界性表皮松解症患者。移植的复合异体活体皮肤等效物由低浓度(5 毫克/毫升)的异体角质形成细胞和成纤维细胞组成,嵌入 I 型胶原凝胶基质中。活体皮肤等效物由 N.K. Koltsov 发育生物学研究所研制。对表面积在 0.4 平方厘米至 120 平方厘米之间的 19 处糜烂和溃疡进行了评估。第 14 天进行临床评估。为了评估表达水平,使用了免疫荧光抗原图谱。 结果:第 14 天,10 个(53%)糜烂处完全闭合。4个(21%)糜烂面积缩小了75%。一个病例(5%)的糜烂面积缩小了 25% 到 75%。4例(21%)未显示临床疗效。胶原蛋白 VII 的表达与基线水平相比有所增加,临床症状也有所改善。 结论:尽管活肤等效疗法与无创伤非粘性敷料在统计学上没有显著差异,但所获得的数据显示了活肤等效疗法的临床疗效。 关键词:遗传性表皮松解症、交界性表皮松解症、隐性萎缩性表皮松解症、糜烂、愈合、局部治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Efficacy of human living skin equivalent in the treatment of inherited epidermolysis bullosa
Background: inherited epidermolysis bullosa is a group of genetic skin disorders caused by mutations in genes encoding structural proteins of epidermis and dermo-epidermal junction. Clinical manifestations are characterized by spontaneous or trauma-induced skin and/or mucosal blistering, and extensive wounds. Cell therapy is considered to be a perspective therapeutic approach in improving wound healing process. Aims: to assess safety and efficacy of human skin equivalent in the treatment of inherited epidermolysis bullosa patients Materials and methods: 7 patients (5 female and 2 male subjects from the age of 20 to 55) with inherited epidermolysis bullosa with different clinical subtypes were enrolled in the study: 3 patients with intermediate recessive dystrophic epidermolysis bullosa, 2 patients with severe recessive dystrophic epidermolysis bullosa, 1 patient with dominant dystrophic epidermolysis bullosa and 1 patient with junctional epidermolysis bullosa. Transplantation of composite allogeneic living skin equivalent comprising allogeneic keratinocytes and fibroblasts in low concentration (5 mg/ml) embedded within a type I collagen gel matrix was performed. The living skin equivalent was developed at N.K. Koltsov Institute of Developmental Biology. 19 erosions and ulcers with a surface area between 0,4 cm2 and 120 cm2 were evaluated. At day 14 clinical assessment was performed. To assess level of expression immunofluorescence antigen mapping was used. Results: at day 14 complete erosion closure was achieved in 10 (53%) erosions. 4 (21%) erosions reduced in size 75%. Size reduction between 25% and 75% was shown in a single (5%) case. No clinical efficacy was demonstrated in 4 (21%) cases. Collagen VII expression increased comparing to baseline level and accompanied clinical improvement. Conclusions: the obtained data showed clinical efficacy of topical treatment with living skin equivalent, although no statistically significant difference was seen between living skin equivalent and atraumatic non-adhesive dressings. Keywords: inherited epidermolysis bullosa, junctional epidermolysis bullosa, recessive dystrophic epidermolysis bullosa, erosions, healing, topical treatment.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
40
审稿时长
8 weeks
期刊最新文献
Perioral dermatitis: nuances of the clinical picture and therapy in different age periods DARIER`S FOLLICULAR DYSKERATOSIS. EXPERIENCE OF SUCCESSFUL THERAPY. Experience of using genetic engineering biological therapy in a patient with psoriasis and chronic renal failure under hemodialysis. Hidradenitis Suppurativa (part 1): definition, epidemiology, etiology, diagnosis. Efficacy and safety of the combined drug (5% benzoyl peroxide + 1% clindamycin) in the treatment of acne: results of an open randomized comparative clinical study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1